Comera SPAC Presentation Deck

Comera Life Sciences Investment Highlights Proprietary Excipient Technology Platform Significant Opportunity Multiple Pharmaceutical Partnerships Proprietary Product Pipeline Expertise and Intellectual Property Compelling Valuation and Attractive Entry Point ● ● ● ● ● )< Comera Proprietary SQore excipient platform technology to develop subcutaneous biologics for improved patient outcomes Lead caffeine-based patented excipient validated in peer-reviewed study and initial in vivo safety studies provide evidence of tolerability Most biologics delivered intravenously despite significant limitations for patients and healthcare system $220B addressable market in 2020 and expected to grow to $422B in 2025 Proprietary pipeline of biologics in development targeting substantial markets and high unmet needs First IND filing expected in Q1 2024 Team with successful track record of drug development and life sciences operating experience Extensive IP protection LIFE SCIENCES Agreements with top-tier pharma collaborators for high-value, late-stage/marketed, licensed products with significant licensing, milestone payment and royalty potential Additional partnerships expected Proprietary platform enables potential for significant value creation As Comera continues to execute on its business plan, it should trade in line with more developed biologics companies that tend to trade at higher valuations 6

View entire presentation